Friedreich Ataxia – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Friedreich Ataxia – Drugs In Development, 2024 report and make more profitable business decisions.
Friedreich’s ataxia (FA) is a neuromuscular disease that mainly affects the nervous system and the heart. FA is a hereditary disease, caused by a defective gene that can be passed down through a family. Signs and symptoms include ataxia, weakness and spasticity, sensory impairment, skeletal abnormalities, cardiac difficulties, and diabetes.
The Friedreich Ataxia drugs in development market research report provide comprehensive information on the therapeutics under development for Friedreich Ataxia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Friedreich Ataxia and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Friedreich Ataxia | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 50 molecules, with 43 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Friedreich Ataxia therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Friedreich Ataxia pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Friedreich Ataxia treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Aclipse Therapeutics LLCAnima Biotech Inc
Astellas Pharma Inc
Autonomous University of Madrid
Biogen Inc
Biointaxis SL
Biovista Inc
Brunel University London
Cellivery Therapeutics Inc
CRISPR Therapeutics AG
Cytonus Therapeutics Inc
Design Therapeutics Inc
Epirium Bio Inc
Fratagene Therapeutics Srl
Fulcrum Therapeutics Inc
Institute for Research in Biomedicine
Ixchel Pharma LLC
Jupiter Neurosciences Inc
Kaleibe
Lacerta Therapeutics Inc
Larimar Therapeutics Inc
Laval University
Lexeo Therapeutics Inc
Metro International Biotech LLC
Minoryx Therapeutics sl
Myto Therapeutics Inc
Nomax Therapeutics Inc
Novartis Gene Therapies
OMEICOS Therapeutics GmbH
Papillon Therapeutics Inc
Pfizer Inc
Prime Medicine Inc
PTC Therapeutics Inc
Retrotope Inc
Scriptr Global Inc
Seelos Therapeutics
Inc.
Solid Biosciences Inc
STATegics Inc
Stealth BioTherapeutics Inc.
StrideBio Inc
University of Pennsylvania
University of Wisconsin Madison
Voyager Therapeutics Inc
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Friedreich Ataxia reports